Physician profile
Christopher Renner
NPI 1003868829
$3,100.36
in general payments reported to CMS, 2019-2025
21 companies · $406 in 2025
The $406 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $260 · 2020: $206 · 2021: $263 · 2022: $1,187 · 2023: $212 · 2024: $566 · 2025: $406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,184.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Notal Vision, INC. | $599.53 | 2022 | |
| Johnson & Johnson Vision Care, INC. | $361.86 | 2019-2024 | Acuvue |
| Alcon Vision LLC | $309.39 | 2020-2025 | Total30, Precision7, Rocklatan |
| Bausch & Lomb Americas INC. | $304.49 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Abbvie INC. | $211.77 | 2022-2024 | |
| Sun Pharmaceutical Industries INC. | $199.94 | 2019-2025 | |
| Tarsus Pharmaceuticals, INC. | $193.04 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $184.22 | 2022-2025 | Tyrvaya, Ryzumvi |
| Sight Sciences, INC. | $91.12 | 2022-2024 | Omni Surgical System |
| Kala Pharmaceuticals, INC. | $87.49 | 2021 | |
| Harrow Eye, LLC | $81.09 | 2024-2025 | Vevye |
| Coopervision INC. | $76.98 | 2019-2022 | |
| Allergan, INC. | $70.94 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $70.67 | 2021-2022 | |
| Maculogix, INC. | $57.60 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $50.37 | 2020-2021 | |
| Thea Pharma INC. | $40.76 | 2024-2025 | Iyuzeh |
| Carl Zeiss Meditec USA, INC. | $34.45 | 2021 | |
| Dompe US, INC. | $31.38 | 2025 | Oxervate |
| Aerie Pharmaceuticals, INC. | $23.81 | 2021 | |
| Shire North American Group INC | $19.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Renner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.